Vuori Kristiina MD 4

What Happened
Kristiina Vuori, M.D., a director of Inhibrx Biosciences, received a derivative equity award on June 3, 2026: a grant covering 15,000 shares listed at $0.00 in the filing (transaction code A). The filing shows the instrument as a derivative award (stock option) rather than an open‑market purchase or sale. Per the filing footnote, the option will be fully exercisable on June 3, 2027, subject to her continued service through that date.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
• Transaction type/code: A = Award/grant (derivative instrument).
• Quantity: 15,000 shares; reported acquisition price: $0.00 (no cash paid at grant per filing).
• Exercisability: Fully exercisable on 2027-06-03, contingent on continued service (per footnote).
• Shares owned after transaction: Not specified in the disclosed data.
• Filing accession: 0001612627-26-000004.

Context
This is a compensation-related option grant to a director, common for aligning management/directors with shareholder interests; it is not an immediate purchase or sale of stock. Such awards do not by themselves indicate bullish or bearish trading intent — any future exercise or sale would generate separate filings (Form 4) when they occur.